I also fail to see downside. Someone implied Resapp didn't...

I also fail to see downside.
Someone implied Resapp didn't address the full spectrum of respiratory disease. However, the most common are covered:- asthma, pneumonia, broncheolitis, bronchitis, croup, urt; working on copd... and it is clearly intended to expand the app as far as it may be possible. How optimistic are you? Seems to me we have a brilliant team with a brilliant model; I am encouraged to be optimistic they will continue to achieve.
Someone suggested we might be heading for a long period without news, following the establishment of FDA application. (implying a dwindling SP). However, it is my understanding that ResApp intends to make multiple FDA applications, one for each disease diagnosis. Inevitably this will result in a staggered release of news. I see this as good.